{"product_id":"promega-ga6000","title":"Promega, GA6000, SIRPα\/CD47 Blockade Bioassay, Fc-Dependent","description":"\u003cp\u003eMeasure Potency and Stability of Biologics that Bind and Block SIRPα\/CD47 Interactions\u003cbr\u003e\nStability-indicating according to ICH guidelines\u003cbr\u003e\n96- and 384-well plate formats\u003cbr\u003e\nNo primary cell culture required\u003cbr\u003e\nSupplied in convenient thaw-and-use format; also available in cell propagation model (CPM) format\u003cbr\u003e\nSpecifications：\u003cbr\u003e\nSIRPα Effector Cells\tGA131A\t1 × 0.5ml\u003cbr\u003e\nCD47 CHO-K1 Target Cells\tGA126A\t1 × 0.5ml\u003cbr\u003e\nFetal Bovine Serum\tJ121A\t1 × 4ml\u003cbr\u003e\nHam's F-12 Medium\tJ123A\t1 × 25ml\u003cbr\u003e\nRPMI 1640 Medium\tG708A\t1 × 36ml\u003cbr\u003e\nBio-Glo-NL™ Luciferase Assay Buffer\tJ308A\t1 × 10ml\u003cbr\u003e\nBio-Glo-NL™ Luciferase Assay Substrate\tJ309A\t1 × 200μl\u003cbr\u003e\nSIRPα Effector Cells\tGA131A\t5 × 0.5ml\u003cbr\u003e\nCD47 CHO-K1 Target Cells\tGA126A\t5 × 0.5ml\u003cbr\u003e\nFetal Bovine Serum\tJ121A\t5 × 4ml\u003cbr\u003e\nHam's F-12 Medium\tJ123A\t5 × 25ml\u003cbr\u003e\nRPMI 1640 Medium\tG708A\t5 × 36ml\u003cbr\u003e\nBio-Glo-NL™ Luciferase Assay Buffer\tJ308A\t5 × 10ml\u003cbr\u003e\nBio-Glo-NL™ Luciferase Assay Substrate\tJ309A\t5 × 200μl\u003cbr\u003e\nCD47 CHO-K1 Target Cells (CPM)\tGA124A\t2 × 1ml\u003cbr\u003e\nSIRPα Effector Cells (CPM)\tGA129A\t2 × 1ml\u003cbr\u003e\nSIRPα Effector Cells (CPM)\tGA129A\t50 × 1ml\u003cbr\u003e\nCD47 CHO-K1 Target Cells (CPM)\tGA124A\t50 × 1ml\u003cbr\u003e\nAntibody-dependent cellular phagocytosis (ADCP) is an important mechanism-of-action (MOA) for antibody-based immunotherapies. ADCP is regulated by a complex network of checkpoints, including SIRPα and CD47, that facilitate removal of aberrant or infected cells while preserving healthy tissues. Despite its important physiological role, the SIRPα\/CD47 checkpoint contributes to immune escape by tumor cells, many of which overexpress CD47 and thereby evade phagocytosis. Biologics that inhibit SIRPα\/CD47 interaction enhance phagocytosis of tumor cells in vitro and have shown promising therapeutic efficacy.\u003cbr\u003e\nCurrent methods for assessing the activity of SIRPα\/CD47 checkpoint inhibitors rely on primary monocyte-derived macrophages and direct measurement of phagocytosis. These assays are laborious and highly variable due to their reliance on donor cells, complex assay protocols and unqualified assay reagents. As a result, these assays are difficult to establish in a quality-controlled setting.\u003cbr\u003e\nThe SIRPα\/CD47 Blockade Bioassay, Fc-Dependent, is a bioluminescent reporter cell-based assay used to measure the potency and stability of ligands or antibodies that bind and block SIRPα and CD47 interactions.\u003c\/p\u003e","brand":"Promega","offers":[{"title":"Default Title","offer_id":46835625066665,"sku":"GA6000","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/promega-ga6000","provider":"Iright","version":"1.0","type":"link"}